CAPR

Capricor Therapeutics' stock has experienced significant volatility over the past six months. The stock saw a substantial increase, driven by FDA regulatory updates and positive clinical data presentations. The company reported a wider-than-expected Q4 2025 loss, leading to a stock price drop. Capricor filed a lawsuit against Nippon Shinyaku, causing shares to fall. There has been insider selling, raising concerns among investors. Analysts generally maintain a "Moderate Buy" or "Strong Buy" rating for Capricor Therapeutics.